Financial Performance - The company's operating revenue for the first half of 2023 was CNY 176,872,071.25, representing a 9.26% increase compared to CNY 161,885,617.06 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 55,812,371.66, a 2.67% increase from CNY 54,360,227.05 in the previous year[24]. - Basic earnings per share for the first half of 2023 were CNY 0.41, up 2.50% from CNY 0.40 in the same period last year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 3.23% year-on-year[26]. - The company achieved operating revenue of CNY 176.87 million in the first half of 2023, a year-on-year increase of 9.26%[54]. - The net profit attributable to shareholders was CNY 55.81 million, reflecting a growth of 2.67% compared to the same period last year[54]. - The company reported a total profit for the first half of 2023 was ¥62,846,060.34, a slight decrease from ¥63,100,581.37 in the same period of 2022[150]. - The company’s total comprehensive income for the first half of 2023 was ¥56,421,052.94, compared to ¥54,537,377.95 in the first half of 2022[151]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 71,395,692.74, a significant decrease of 859.86% compared to a positive cash flow of CNY 9,395,849.83 in the same period last year[24]. - Operating cash flow showed a significant decline, with a net outflow of CNY 71.40 million, compared to a net inflow of CNY 9.40 million in the previous year[62]. - Total cash inflow from operating activities decreased to 127,141,917.65 RMB in H1 2023, down 29.5% from 180,429,676.75 RMB in H1 2022[156]. - Cash outflow from operating activities increased to 198,537,610.39 RMB in H1 2023, compared to 171,033,826.92 RMB in H1 2022, reflecting a rise of 16.1%[156]. - The company reported a significant increase in cash and cash equivalents at the end of H1 2023, totaling 224,495,448.66 RMB, down from 414,146,712.82 RMB at the end of H1 2022[157]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,242,440,463.80, reflecting a 3.64% increase from CNY 1,198,844,121.40 at the end of the previous year[24]. - Current liabilities decreased to CNY 100,144,137.98 from CNY 113,243,848.53, a reduction of about 11.5%[143]. - Total liabilities increased to CNY 102,419,137.98 from CNY 115,583,848.53, a decrease of about 11.4%[144]. - The company's total current assets amounted to RMB 804,145,980.53, a decrease from RMB 829,966,363.51 at the end of 2022, reflecting a decline of approximately 3.9%[142]. - The company's cash and cash equivalents were reported at RMB 257,524,911.67, down from RMB 366,273,999.90, indicating a decrease of about 29.8%[142]. Investments and Subsidiaries - The company has invested ¥30 million in the Shanghai Hongsheng Houde Private Equity Investment Fund, representing an 8.1079% stake, focusing on the healthcare sector[72]. - The company is actively optimizing the equity structure of its subsidiaries and expanding its investment in the healthcare industry through private equity funds[69]. - The company’s subsidiary, Wei Le Hai Ci, reported total assets of €30,551.50 million and a net profit of €306.94 million[74]. - The subsidiary, Shan Tao Information, had total assets of ¥28,283.34 million and a net profit of ¥2,135.49 million[74]. - The company completed the transfer of 100% equity of Boke Medical for 5.33 million RMB, which is no longer included in the consolidated financial statements[84]. Market Position and Strategy - The company is positioned to benefit from the increasing demand for intelligent pharmaceutical management systems as traditional methods become insufficient[33]. - The company aims to expand its market presence by exploring overseas markets and replicating successful business models like the "Zhongxiang model"[53]. - The company signed a joint venture agreement with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to expand into the Middle East and North Africa markets[55]. - The company is actively promoting the "Zhongxiang Model" for replicable "to-G" business, enhancing cooperation with local governments to develop healthcare projects[56]. - The company has established a strategic partnership to enhance its product line and expand its market presence in the healthcare sector[69]. Research and Development - Research and development expenses increased by 5.49% to CNY 10.95 million, reflecting the company's commitment to new product development[62]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[42]. - The company has established a comprehensive R&D system with nearly 20 years of experience in intelligent drug management, ensuring strong innovation capabilities[46]. Risks and Challenges - The company has highlighted potential risks in its operations, urging investors to pay attention to these risks[7]. - The industry is in a recovery phase post-pandemic, with clients in the hospital and pharmaceutical distribution sectors facing financial constraints[26]. - The company has faced challenges such as economic pressures and regulatory actions in the pharmaceutical sector but continues to strengthen its market position[53]. Shareholder Commitments and Governance - The company has a long-term commitment from major shareholders to ensure stability in shareholding structure[94]. - The company will not repurchase shares during the lock-up period and will ensure compliance with all relevant laws and regulations regarding share transfers[99]. - The company commits that the prospectus does not contain false records, misleading statements, or major omissions, and assumes legal responsibility for its authenticity, accuracy, and completeness[112]. - The controlling shareholders commit to avoid any competition with the company and will not engage in similar business activities that could harm the company's interests[115]. - Major shareholders are also bound to fulfill their commitments and must extend their lock-up period until all negative impacts from any non-fulfillment are resolved[108].

证券简称：健麾信息 证券代码：605186 公告编号：2023-018 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 投资标的名称：厦门精配软件工程有限公司（以下简称"厦门精配"） 投资金额：上海健麾信息技术股份有限公司（以下简称"公司"、"健麾 信息"）基于公司发展战略对厦门精配以现金方式增资 2250 万元，增资完成后 公司持有厦门精配 15% 的股权。 上海健麾信息技术股份有限公司 关于对外投资的公告 重要内容提示： 2 基于公司战略规划和经营发展的需要，此次投资将进一步整合双方软硬 件技术、产业渠道等优势资源，通过优化资源配置，形成产业聚集优势，巩 固公司在行业内的核心竞争力。 公司与厦门精配于近日签署《增资协议》及《股东间协议》，公司拟以 自有资金现金方式对厦门精配增资，增资金额为人民币 2250 万元，其中 284.3243 万元计入注册资本，其余金额计入厦门精配资本公积金。此次增资 完成后，公司持有厦门精配 15%的股权。 （二）审议决策情况 本次交易不构成关联交易或同业竞争，不构成重大资产重组；本次交 ...

证券代码：605186 证券简称：健麾信息 公告编号：2023-017 上海健麾信息技术股份有限公司 关于拟购买土地使用权建设钟祥智能制造基地暨签 署医药数字化项目合同的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海健麾信息技术股份有限公司（以下简称"公司"）于2022年9月10日、 2022年9月15日、2022年11月26日、2022年12月03日、2022年12月13日在上海 证券交易所网站（www.sse.com.cn）分别披露《关于拟购买土地使用权建设钟 祥智能制造基地暨签署医药数字化项目合同的公告》、《关于拟购买土地使用 权建设钟祥智能制造基地暨签署医药数字化项目合同的补充公告》、《关于拟 购买土地使用权建设钟祥智能制造基地暨签署医药数字化项目合同的进展公 告》（公告编号：2022-034、2022-035、2022-041、2022-042、2022-043）。 一、交易进展情况 公司全资子公司湖北健麾信息技术有限公司按照法定程序参与了钟祥市自然 资源和规划局发布的国有土地使用权挂牌出让竞拍，以人 ...

016 证券代码：605186 证券简称：健麾信息 公告编号：2023- 上海健麾信息技术股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.09 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/24 | － | 2023/8/25 | 2023/8/25 | 差异化分红送转： 否 本次利润分配方案经公司 2023 年 6 月 29 日的 2022 年年度股东大会审议通过。具体内容详见 公司于 2023 年 6 月 30 日刊登在《上海证券报》《中国证券报》《证券时报》《证券日报》及 上海证券交易所网站（www.sse.com.cn）的《2022 年年度股东大会决议公告》（公告编号：2023- 014）。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 ...

证券代码：605186 证券简称：健麾信息 公告编号：2023-012 上海健麾信息技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 上海健麾信息技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入 地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 06 月 15 日 下午 15:00-16:00 举行 2022 年度业绩说明会，就投资者关 心的问题进行交流。 一、 说明会类型 会议召开时间：2023 年 06 月 15 日(星期四) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 08 日(星期四) 至 06 月 14 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2022 is CNY 115,681,544.43, with a total distributable profit of CNY 217,201,772.33 as of December 31, 2022[5]. - The proposed cash dividend is CNY 0.90 per 10 shares (including tax), totaling CNY 12,240,000.00, which represents 10.58% of the net profit attributable to the parent company[5]. - The company's operating revenue for 2022 was CNY 322,359,785.92, a decrease of 34.18% compared to CNY 489,755,358.90 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 115,681,544.43, down 1.65% from CNY 117,618,137.99 in 2021[25]. - The cash flow from operating activities showed a net outflow of CNY -37,261,950.98 in 2022, a decline of 169.22% compared to CNY 53,827,755.74 in 2021[25]. - The basic earnings per share for 2022 was CNY 0.85, a decrease of 1.16% from CNY 0.86 in 2021[27]. - The total assets at the end of 2022 were CNY 1,198,844,121.40, an increase of 6.13% from CNY 1,129,566,326.94 at the end of 2021[26]. - The company reported a decrease in the weighted average return on equity to 12.11% in 2022 from 13.64% in 2021, a reduction of 1.53 percentage points[27]. - The net profit after deducting non-recurring gains and losses was CNY 96,730,991.02, down 10.31% from CNY 107,847,786.04 in 2021[25]. - The total net assets attributable to shareholders increased to CNY 1,004,966,459.25 at the end of 2022, up 11.47% from CNY 901,524,914.82 at the end of 2021[25]. Business Operations and Strategy - The company experienced a significant decline in revenue due to external factors affecting the supply-demand relationship in the industry[27]. - The company secured a CNY 69 million contract for the "Zhongxiang Smart Medical Integrated Project," expanding its "To-G" bulk model business[36]. - The company established joint ventures in various fields, including unmanned medicine dispensing machines and automated logistics, indicating a strategic expansion into new business areas[37]. - A joint venture was signed with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to enhance the company's presence in the Middle East and North Africa markets[38]. - The company focused on improving operational capabilities and management efficiency, implementing strict budget controls and lean production management[39]. - The company is actively pursuing opportunities in the smart pharmaceutical management sector, driven by increasing demands for efficiency and quality in drug dispensing[44]. - The establishment of centralized intravenous medication preparation centers is creating further development space for high-tech automation in the pharmaceutical management field[45]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[55]. - The company’s projects involve a comprehensive approach including hardware and software integration, system design, and ongoing maintenance services[57]. Market Trends and Growth Potential - The global market for automated pharmacy systems is growing, with the average adoption rate in developed countries around 30% as of 2013[43]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, highlighting the trend towards automation in healthcare[43]. - The market for retail pharmacies is expected to grow due to the rise of internet healthcare and automation, with a focus on O2O models[48]. - The company is focusing on expanding its market presence in Hubei and surrounding provinces, leveraging synergies with its existing products[110]. - The market penetration rate of automated pharmacy equipment in China is expected to increase significantly due to rising healthcare investments and policy support, with a projected growth in the industry[111]. - By 2023, the penetration rates for automated pharmacy equipment in various cities are forecasted to rise: Beijing from 4% to 45%, Shenzhen from 6% to 57%, Suzhou from 30% to 65%, and Shanghai from 5% to 48%[112]. Research and Development - The total R&D expenditure amounted to CNY 22,415,836.21, representing 6.95% of operating income[85]. - The company has 70 R&D personnel, accounting for 19.23% of the total workforce[86]. - The company aims to enhance its R&D capabilities and product development, focusing on market-oriented strategies and leveraging technologies like machine vision and deep learning[116]. - A talent development plan will be implemented to strengthen the R&D team and attract experienced professionals to support the company's growth[121]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[3]. - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The internal control system was evaluated as effective, with no significant deficiencies found in financial reporting controls[165]. - The company has established specialized committees under the board, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[147]. - The company has no reported penalties from securities regulatory agencies in the past three years[145]. - The company has maintained a stable leadership structure, with key executives serving since 2017, ensuring continuity in management and strategic direction[137]. Shareholder Relations and Commitments - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with a lock-up extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[180]. - The company has reiterated its commitment to adhere to all relevant laws and regulations regarding shareholding and transfer practices[178]. - The company will ensure compliance with all relevant laws and regulations regarding share repurchase and management[187]. - Major shareholders, including the controlling shareholders, have committed to fulfilling all obligations related to public commitments made during the IPO process[190]. - The company guarantees that the prospectus for the IPO does not contain false records or misleading statements, and it will bear legal responsibility for its accuracy[193].

Financial Performance - The company's operating revenue for Q1 2023 was ¥61,275,234.89, representing a year-on-year increase of 35.03%[5] - The net profit attributable to shareholders for the same period was ¥9,943,347.23, reflecting a growth of 40.98% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.07, an increase of 40.00% year-on-year[6] - The weighted average return on equity rose to 0.98%, an increase of 0.20 percentage points from the previous year[6] - The company reported a significant increase in sales revenue from services, contributing to the overall revenue growth[23] - The financial outlook remains positive, with expectations for continued revenue growth and improved profitability in the upcoming quarters[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,198,379,220.88, showing a slight decrease of 0.04% compared to the end of the previous year[6] - As of March 31, 2023, the total assets of the company amounted to CNY 1,198,379,220.88, slightly down from CNY 1,198,844,121.40 at the end of 2022[17] - The company's current assets totaled CNY 776,059,761.70, a decrease from CNY 829,966,363.51 at the end of 2022, indicating a decline of approximately 6.5%[18] - The company's non-current assets increased to CNY 422,319,459.18 from CNY 368,877,757.89, reflecting an increase of about 14.4%[18] - The total liabilities of the company were CNY 106,860,248.96, down from CNY 115,583,848.53, representing a decrease of approximately 7.4%[19] - The company's cash and cash equivalents were CNY 303,158,377.31, down from CNY 366,273,999.90, indicating a decline of about 17.2%[17] Cash Flow - The net cash flow from operating activities was negative at -¥46,915,420.31, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥46,915,420.31, an improvement from a net outflow of ¥60,500,250.05 in Q1 2022[27] - The net cash flow from investing activities was -$40,960,093.79, an improvement from -$47,339,470.31 in the previous period[28] - The net cash flow from financing activities was $24,735,729.17, with cash inflow from borrowings amounting to $25,000,000.00[28] - The total cash and cash equivalents at the end of the period decreased to $270,988,348.82 from $360,524,063.75, reflecting a net decrease of $63,115,622.59[28] Expenses - The company reported a 75.28% increase in operating costs, which aligned with the revenue growth during the period[11] - Operating costs amounted to ¥51,831,889.26, up from ¥34,700,305.33, reflecting a significant increase in expenses[23] - Research and development expenses were ¥5,567,972.60, slightly down from ¥5,569,046.07 in the previous year[24] Receivables and Inventory - The company experienced a 68.21% increase in other receivables, attributed to an increase in land deposit guarantees[10] - The company's inventory increased to CNY 91,289,460.26 from CNY 74,023,447.28, reflecting an increase of about 23.4%[18] - Accounts receivable decreased to CNY 301,081,720.73 from CNY 332,887,498.88, a reduction of approximately 9.5%[18] - The company’s other receivables increased to CNY 18,214,695.02 from CNY 10,828,485.10, an increase of approximately 68.5%[18] Borrowings - Short-term borrowings increased by 100.00% during the reporting period, indicating a rise in bank short-term loans[11] - The company reported a decrease in short-term borrowings to CNY 25,000,000.00, indicating a reduction in leverage[19] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[28]

Group 1: Company Performance and Recovery - The company resumed full operations on June 1, 2022, after being approved as a second batch of companies for resumption in Shanghai [3] - The overall business performance remained stable despite the impact of the COVID-19 pandemic [3] - The company has implemented refined management strategies to adapt to the pandemic situation [4] Group 2: Market Position and Client Base - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, with more than half of the top 100 hospitals in China as clients [3] - The company focuses on the pharmaceutical intelligent management sector and has a strong market presence in economically developed coastal regions, particularly in first and second-tier cities [4] Group 3: Future Strategy and Business Development - In 2022, the company aims to enhance product development and market expansion while optimizing production and management efficiency [4] - The company plans to explore the "to-G" market and increase its market share in the retail pharmaceutical sector [4] - The company has a strategic layout for the retail market and aims to penetrate lower-tier medical service institutions [4]

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第三季度报告 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 113,472,020.66 | -14.92 | 275,357,637.72 | -3.4 | | 归属于上市公司股东 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,885,617.06, representing a 6.74% increase compared to ¥151,665,389.91 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥54,360,227.05, up 5.02% from ¥51,762,534.45 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥51,610,072.47, which is an increase of 11.20% compared to ¥46,411,777.07 in the same period last year[20]. - The basic earnings per share was CNY 0.40, up 5.26% from CNY 0.38 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.40, reflecting a 5.26% increase year-on-year[21]. - The weighted average return on equity was 5.85%, down 0.32 percentage points from the previous year[21]. - The weighted average return on assets after deducting non-recurring gains and losses increased by 0.03 percentage points to 5.56%[21]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[97]. - The company recorded a comprehensive income of CNY 54,360,227.05 for the first half of 2022, indicating positive performance in its financial results[171]. Cash Flow and Assets - The net cash flow from operating activities decreased by 65.81%, amounting to ¥9,395,849.83, down from ¥27,478,194.54 in the previous year[20]. - The company's cash and cash equivalents decreased by 11.57% to 414.65 million yuan compared to the previous year[63]. - The company's inventory decreased by 20.90% to 48.03 million yuan compared to the previous year[63]. - The total current assets decreased to ¥799,579,832.93 from ¥850,687,666.75, reflecting a decline of approximately 6%[148]. - Cash and cash equivalents decreased to ¥414,646,712.82 from ¥468,916,999.82, a reduction of about 11.5%[148]. - The company reported a net decrease in cash and cash equivalents of CNY -56,488,152.25, an improvement from CNY -234,215,319.20 in the prior year[167]. Business Operations and Strategy - The company faced challenges due to the COVID-19 pandemic, affecting project timelines and operational cash flow[21]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[41]. - The company aims to strengthen its market position as public hospitals' roles are expected to be reinforced by government policies[35]. - The retail pharmacy market share is anticipated to increase due to the rapid development of internet healthcare and automation in drug management[35]. - The company is focusing on building an industrial ecosystem and expanding into related business areas, including automation in wards and operating rooms[56]. Research and Development - Research and development expenses amounted to 10.38 million yuan, representing a growth of 5.72% compared to the previous year[57]. - The company has established a comprehensive R&D system with nearly 20 years of experience in intelligent drug management, enhancing its innovation capabilities[45]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving operational efficiency and product quality[103]. Shareholder Commitments and Governance - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with an automatic extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[104]. - Major shareholders, including Ningbo Hydra, have pledged to hold 1,020,000 shares without transfer or management delegation for 36 months post-IPO[105]. - The controlling shareholder, Dai Jianwei, plans to support the company's development and will not reduce shareholdings below the IPO price for two years post-lock-up, with annual reductions capped at 25% of their holdings[107]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days within three years post-IPO[109]. - The company guarantees that the prospectus for the IPO does not contain false statements or omissions, and will compensate investors for losses if such issues are identified[117]. Market Position and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[101]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration[102]. - The company has provided intelligent drug management projects for over 700 medical institutions, including top hospitals in China[36]. Financial Health and Liabilities - Total liabilities decreased to ¥94,769,032.15 from ¥154,027,955.51, a significant reduction of about 38.5%[150]. - The company reported a significant reduction in tax payables by 51.60% to CNY 17.24 million, attributed to early payments of VAT and corporate income tax[65]. - The company's accounts payable decreased by 59.72% to CNY 13.09 million, mainly due to the settlement of large project payments[65]. Compliance and Legal Matters - The company has not engaged in any significant litigation or arbitration matters during the reporting period[126]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[126]. - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[126].